Form 4: Whitehawk Therapeutics Director Acquires Shares

Whitehawk Therapeutics, Inc. reports a Form 4 filing detailing a Director's acquisition of common stock and pre-funded warrants.

Summary

• Castelein Caley, a Director at Whitehawk Therapeutics, Inc., acquired 255,102 shares of common stock on May 14, 2026, at a price of $3.92 per share.
• Following this transaction, the reporting person beneficially owns 274,796 shares of common stock directly.
• Additionally, a pre-funded warrant to acquire 2,072,756 shares of common stock was acquired by KVP Capital, LP, where Castelein Caley is the Managing Director.
• This pre-funded warrant has an exercise price of $0.0001 and is subject to a beneficial ownership limitation of 4.99% of the outstanding common stock.
• The reporting person disclaims beneficial ownership of shares and warrants held by KVP Capital, LP, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports a standard insider transaction with a disclaimer of full beneficial ownership, which tempers the positive signal of a director purchase.

Positives

• Director acquisition of common stock indicates confidence in the company's future.
• Acquisition of pre-funded warrants suggests a long-term investment perspective.

Negatives

• The reporting person disclaims beneficial ownership of a significant portion of the acquired securities, which could indicate a lack of direct control or personal financial commitment beyond a pecuniary interest.

Risks

• The exercise of pre-funded warrants is limited by a 4.99% beneficial ownership cap, which could restrict future share acquisition.
• Potential for conflicts of interest given the reporting person's role as Managing Director of KVP Capital, LP, which holds a substantial number of securities.

Future Outlook

The filing does not contain forward-looking statements or guidance. The pre-funded warrant is exercisable on or after May 14, 2026, until exercised in full, subject to ownership limitations.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. Director purchases can often be interpreted as a positive signal by the market, suggesting internal confidence in the company's prospects.

Related Party Transactions

• The reporting person, Castelein Caley, is the Managing Director of KVP Capital, LP, which acquired a pre-funded warrant. This represents a related party transaction.

Stakeholder Impact

• Shareholders may view the director's purchase positively, signaling confidence, but the disclaimer of full beneficial ownership might introduce some ambiguity.
• Creditors and other stakeholders are not directly impacted by this transaction.

Next Steps

• The pre-funded warrant can be exercised by the holder at any time on or after May 14, 2026, until it has been exercised in full.
• The reporting person may exercise their pecuniary interest in the securities held by KVP Capital, LP.

Key Dates

Keywords

Form 4, SEC Filing, Whitehawk Therapeutics, WHWK, Insider Trading, Stock Acquisition, Director, Beneficial Ownership, Pre-funded Warrant, KVP Capital